We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study.
- Authors
Watari, Ikue; Oka, Shiro; Tanaka, Shinji; Aoyama, Taiki; Imagawa, Hiroki; Shishido, Takayoshi; Yoshida, Shigeto; Chayama, Kazuaki
- Abstract
<bold>Background: </bold>Treatment of low-dose aspirin (LDA)-induced small-bowel injury has not been established. Polaprezinc, a chelate of zinc and L-carnosine, may be efficacious for such injury. We conducted a pilot randomized controlled study to investigate whether polaprezinc is effective against LDA-induced small-bowel injuries.<bold>Methods: </bold>Consecutive patients under long-term (>3 months) LDA treatment and who agreed to participate in our study underwent initial capsule endoscopy (CE). Patients with LDA-induced small-bowel injury apparent upon initial CE (n = 20) were randomized into a polaprezinc (150 mg/day for 4 weeks) group and a control (no polaprezinc treatment) group. All underwent follow-up CE after 4 weeks. Changes in the number and characteristics of small-bowel mucosal injuries were compared within and between the two groups.<bold>Results: </bold>The median number of reddened lesions and erosions/ulcers upon follow-up CE in the polaprezinc group significantly decreased (P < 0.05). However, there was no significant difference in the median number of reddened lesions and erosions/ulcers upon follow-up CE in the control group.<bold>Conclusions: </bold>Co-administration of polaprezinc may be effective against small-bowel mucosal injury associated with long-term LDA therapy.
- Subjects
ASPIRIN; INTESTINAL diseases; CAPSULE endoscopy; EXAMINATION of the gastrointestinal system; CARNOSINE; DIPEPTIDES
- Publication
BMC Gastroenterology, 2013, Vol 13, Issue 1, p1
- ISSN
1471-230X
- Publication type
journal article
- DOI
10.1186/1471-230X-13-108